Targeting a specific pathway in aggressive nerve tumors associated with NF1.
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
This study is looking at how certain genetic changes in aggressive tumors related to neurofibromatosis type 1 can make them hard to treat, and it’s testing a new combination therapy that might help improve treatment for patients with these tumors.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11034089 on NIH RePORTER |
What this research studies
This research focuses on malignant peripheral nerve sheath tumors (MPNSTs), which are aggressive cancers often linked to neurofibromatosis type 1 (NF1). The study aims to understand how certain genetic alterations contribute to the resistance of these tumors to existing treatments. By analyzing tumor samples and using preclinical models, researchers are investigating a novel combination therapy that targets specific pathways involved in tumor growth. This approach could potentially improve treatment outcomes for patients with NF1-related MPNSTs.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with NF1 and malignant peripheral nerve sheath tumors.
Not a fit: Patients with MPNSTs not associated with NF1 or those with other types of tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from NF1-related malignant peripheral nerve sheath tumors.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other tumor types, suggesting potential for success in this novel approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Chi, Ping — Sloan-Kettering Inst Can Research
- Study coordinator: Chi, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.